Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07765823 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Role of N-Acetylcysteine in Non-Acetaminophen-Induced Liver Failure

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 19, 2026 (before its estimated October 15, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study Identification, Study Status, Sponsor/Collaborators, Conditions, Outcome Measuresv2
  2. Study First Submitted
This randomized controlled trial evaluates whether oral N-acetylcysteine (NAC), given alongside standard supportive care, improves survival and reduces mortality in patients with non-acetaminophen-induced acute liver failure (ALF), compared to supportive care alone. Secondary objectives are to assess NAC's effect on length of hospital stay and improvement in liver function tests. Sixty-two adult patients (18-60 years) will be randomized 1:1 to NAC or control, with outcomes assessed at 28 days (survival/mortality) and day 4 (liver function tests).
Trial Details
NCT Number NCT07765823
Lead Sponsor King Edward Medical University
Conditions
(from sponsor)		 Acute Liver Failure
Related terms Liver Failure, Liver Failure, Acute
Enrollment 62 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov